Changchun High-Tech Industries News

Changchun High-Tech Industry 2024 Profit Falls 43%; Shares Down 5%

MT NewswiresApr 21 02:16 ET

Performance reversal! Net profit plummets by over 40%, leading hormone giant approaches limit down during trading.

The performance of three out of the four main businesses has declined.

Gelonghui FinanceApr 20 22:56 ET

Changchun Hi-Tech: 2024 Annual Report Summary

SZSIApr 20 12:00 ET · Announcements

Changchun Hi-Tech: Report for the first quarter of 2025

SZSIApr 20 12:00 ET · Announcements

Changchun Hi-Tech: 2024 Annual Report

SZSIApr 20 12:00 ET · Announcements

Changchun High-Tech Industries (000661.SZ) released its 2024 performance report, with a net income of 2.583 billion yuan, a decrease of 43.01% year-on-year.

Changchun High-Tech Industries (000661.SZ) disclosed its annual report for 2024, reporting revenue of 134.6...

Zhitong FinanceApr 20 04:22 ET

Express News | Changchun High-Tech Industry 2024 Net Profit Down 43.0% Y/Y

ReutersApr 20 04:02 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET

Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Shares Not Telling The Full Story

Simply Wall StApr 4 21:22 ET

Changchun High-Tech Industry's Subsidiary Gets Nod to Trial Solid Tumor Drug

MT NewswiresApr 2 02:25 ET

Changchun High-Tech Industries (000661.SZ) has repurchased a total of 0.67% of its shares, spending approximately 0.3 billion yuan.

Changchun High-Tech Industries (000661.SZ) announced that as of March 31, 2025, through centralized competitive trading...

Zhitong FinanceApr 1 07:12 ET

Changchun High-Tech Industry's Subsidiary Gets Nod to Trial Rheumatoid Arthritis Drug in US

MT NewswiresMar 21 04:53 ET

Changchun High-Tech Industries (000661.SZ): The clinical trial application for the new drug GenSci120 injection from the subsidiary has received implied approval from the FDA in the USA.

Gelonghui March 20th丨Changchun High-Tech Industries (000661.SZ) announced that recently, Changchun High-Tech Industries (Group) Co., Ltd.'s holding subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical") received notification from the USA Food and Drug Administration (referred to as "USA FDA") that JinSai Pharmaceutical's GenSci120 injection new drug clinical trial application has obtained implied approval. GenSci120 injection is a humanized PD-1 monoclonal antibody developed by JinSai Pharmaceutical, which activates the PD-1 inhibitory signaling pathway and ADCC effects by binding to PD-1, thus inhibiting.

Gelonghui FinanceMar 20 04:18 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Individual Investors in Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 7.2% Last Week

Simply Wall StMar 14 20:06 ET

Changchun High-Tech Industry Gets Nod to Amend Growth Hormone Drug

MT NewswiresMar 4 23:28 ET

Changchun High-Tech Industries (000661.SZ): The subsidiary's polyethylene glycol recombinant human growth hormone injection has received approval for a supplemental application to increase the approved indications of the same variety in the domestic marke

On March 4, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that recently, its subsidiary—Changchun Jin Sai Pharmaceutical Co., Ltd. (referred to as "Jin Sai Pharmaceutical")—received approval from the National Medical Products Administration for a supplementary application for the already approved indications of its polyethylene glycol recombinant human growth hormone injection (branded as Jin Sai Zeng) in the domestic market. Following the approval from the National Medical Products Administration, two specifications of Jin Sai Zeng (54IU/9.0mg/1.0ml/bottle, 27IU/4.5mg/0.5ml/bottle) have been approved for endogenous use.

Gelonghui FinanceMar 4 04:12 ET

Changchun High-Tech Industries (000661.SZ): A cumulative repurchase of 0.67% of shares.

Glory Exchange, March 3 - Changchun High-Tech Industries (000661.SZ) announced that as of February 28, 2025, the company has cumulatively repurchased 2,734,617 shares through a special securities repurchase account via centralized bidding, accounting for 0.67% of the company's total share capital, with the highest Fill Price being 112.25 yuan/share and the lowest Fill Price being 106.62 yuan/share, totaling a transaction amount of 299,997,006.34 RMB (including transaction fees). The implementation of the company's share repurchase complies with relevant laws and regulations as well as the company's established share repurchase plan.

Gelonghui FinanceMar 3 04:11 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

A Look At The Intrinsic Value Of Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661)

Simply Wall StFeb 24 19:43 ET